SOCIAL AND HEALTH SERVICES
(Medical Assistance Administration)
Purpose: To correct a typographical error in a cross-reference. The introduction to WAC 388-530-1280 refers to RCW 69.41.090; the correct reference is RCW 69.41.190.
Citation of Existing Rules Affected by this Order: Amending WAC 388-530-1280.
Statutory Authority for Adoption: RCW 69.41.190, 70.14.050, and 74.08.090.
Adopted under notice filed as WSR 05-06-095 on March 1, 2005.
Number of Sections Adopted in Order to Comply with Federal Statute: New 0, Amended 0, Repealed 0; Federal Rules or Standards: New 0, Amended 0, Repealed 0; or Recently Enacted State Statutes: New 0, Amended 0, Repealed 0.
Number of Sections Adopted at Request of a Nongovernmental Entity: New 0, Amended 0, Repealed 0.
Number of Sections Adopted on the Agency's Own Initiative: New 0, Amended 0, Repealed 0.
Number of Sections Adopted in Order to Clarify, Streamline, or Reform Agency Procedures: New 0, Amended 1, Repealed 0.
Number of Sections Adopted Using Negotiated Rule Making: New 0, Amended 0, Repealed 0; Pilot Rule Making: New 0, Amended 0, Repealed 0; or Other Alternative Rule Making: New 0, Amended 1, Repealed 0.
Date Adopted: May 10, 2005.
Andy Fernando, Manager
Rules and Policies Assistance Unit3519.2
(1) The Washington preferred drug list (PDL):
(a) Washington state contracts with evidence-based practice center(s) for systematic reviews of drug(s).
(b) The pharmacy and therapeutics (P&T) committee reviews and evaluates the safety, efficacy, and outcomes of prescribed drugs, using evidence-based information provided by the evidence-based practice center(s).
(c) The P&T committee makes recommendations to state agencies as to which drug(s) to include on the Washington PDL, under chapter 182-50 WAC.
(d) The appointing authority makes the final selection of drugs included on the Washington PDL.
(e) Nonpreferred drugs within a therapeutic class on the Washington PDL are subject to the therapeutic interchange program (TIP) according to WAC 388-530-1290.
(2) The medical assistance administration's (MAA's) PDL. Drugs on MAA's PDL:
(a) Are not part of the Washington PDL;
(b) Are not subject to TIP; and
(c) Continue to require prior authorization when they are designated as nonpreferred.
(3) Combination drugs that are not on the Washington PDL, that are not reviewed by the evidence-based practice center(s), and that are not subject to TIP under WAC 388-530-1290, are considered for coverage according to MAA's prior authorization program.
[Statutory Authority: RCW 74.08.090, 70.14.050, 69.41.150, 69.41.190, chapter 41.05 RCW. 05-02-044, § 388-530-1280, filed 12/30/04, effective 1/30/05.]